Akanda

Akanda Earnings Yield

The Earnings Yield of Akanda (AKAN) as of Oct 26, 2026 is -2,818.31 %. In the previous year, Earnings Yield was -252.86 % — a change of 1,014.59% (lower).

Earnings Yield

-2,818.31 %

YoY

1,014.59%

Last updated:

Earnings Yield of Akanda is 2025 -2,818.31 % . Earnings Yield of Akanda was 2024 -252.86 % . It decreases by 1,014.59% lower compared to the previous year.

The Akanda Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2019
-116.58 USD
Jan 1, 2020
-142.02 USD
Jan 1, 2021
-501.96 USD
Jan 1, 2022
-719.65 USD
Jan 1, 2023
-1,992.41 USD
Jan 1, 2024
-252.86 USD
Jan 1, 2025
-2,818.31 USD
The Akanda Earnings Yield history
YEAREarnings YieldYoY
-2,818.31 %+1,014.59%
-252.86 %-87.31%
-1,992.41 %+176.86%
-719.65 %+43.37%
-501.96 %+253.44%
-142.02 %+21.82%
-116.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Earnings Yield of Akanda is -2,818.31 % in 2025.

Earnings Yield of Akanda changed from -252.86 % to -2,818.31 %, representing a 1,014.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Akanda since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Akanda with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Akanda

All Key Metrics — Akanda